JAZZ - Axsome: A Growth Transition April, 13 2022 12:04 PM Jazz Pharmaceuticals plc The recent Sunosi acquisition delivers pipeline synergy as well as making Axsome revenue positive. AXS07 is poised to gain FDA approval to better serve patients afflicted by migraines. AXS05's regulatory issues are now seemingly cleared with approval anticipated for either Q3 or Q4 this year. For further details see: Axsome: A Growth Transition